Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer

PURPOSE: S-trans,trans-Farnesylthiosalicylic Acid (FTS, salirasib) inhibits Ras-dependent cell growth by dislodging all isoforms of Ras, including mutant Ras, from the plasma membrane. This study evaluated the activity, safety, and toxicity of salirasib in preclinical models and patients with metast...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Laheru, Daniel, Shah, Preeti, Rajeshkumar, N. V., McAllister, Florencia, Taylor, Gretchen, Goldsweig, Howard, Le, Dung T., Donehower, Ross, Jimeno, Antonio, Linden, Sheila, Zhao, Ming, Song, Dongweon, Rudek, Michelle A., Hidalgo, Manuel
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3557459/
https://ncbi.nlm.nih.gov/pubmed/22547163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9818-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi